A5087132061- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- Rheumatoid Arthritis Research and Therapies
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical studies and practices
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Autoimmune and Inflammatory Disorders Research
- Long-Term Effects of COVID-19
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- Inflammatory Bowel Disease
- Nutrition and Health in Aging
- Electronic Health Records Systems
- Medication Adherence and Compliance
- Lymphoma Diagnosis and Treatment
- Pharmacy and Medical Practices
- Cancer Treatment and Pharmacology
- Celiac Disease Research and Management
- Biosimilars and Bioanalytical Methods
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Autoimmune Bullous Skin Diseases
- Multiple and Secondary Primary Cancers
Hospital Universitario Infanta Leonor
2016-2024
Hospital Universitario de La Princesa
2018-2020
Comunidad de Madrid
2019-2020
Madrid Health Service
2016-2020
Hospital Universitario 12 De Octubre
2013-2014
Agencia Española de Medicamentos y Productos Sanitarios
2014
Research Institute Hospital 12 de Octubre
2012-2013
Hospital Universitario Miguel Servet
2013
<h3>Background and Importance</h3> The new intramuscular antiretroviral treatments (IM-ART), cabotegravir-rilpivirine, have represented a breakthrough in reducing stigma improving adherence among HIV patients. However, it is necessary to understand how their real-world use impacts patient outcomes. <h3>Aim Objectives</h3> To assess the effectiveness safety of IM-ART settings investigate impact on analytical parameters. <h3>Material Methods</h3> A retrospective observational study conducted...
Background/Objective There is evidence supporting that there are no relevant clinical differences between dosing rituximab 1000 mg or 2000 per cycle in rheumatoid arthritis (RA) patients trials, and low-dose cycles seem to have a better safety profile. Our objective was describe the pattern of use real-life practice conditions. Methods Rituximab for RA (RITAR) study retrospective cohort from 2005 2015. Eligibility criteria were adults treated with active articular disease. Response duration...
<h3>Background</h3> For novel direct acting antiviral (DAA) drugs, HIV/HCV patients have achieved similar sustained virologic response rates as HCV monoinfected patients, but experience in safety and drug interactions with antiretroviral (ARV) regimens is limited clinical practice, especially cirrhotic patients. <h3>Purpose</h3> We evaluated the of DAA ARV drugs co-infected HIV-1 treated at hospital from January to September 2015. <h3>Material methods</h3> HCV/HIV on stable were enrolled...
<h3>Background</h3> Rituximab (RTX) is a B-lymphocyte depleting monoclonal antibody that was approved for rheumatoid arthritis (RA) treatment in Europe 2006. <h3>Objectives</h3> To analyse factors affecting long term persistence of RTX the RA patients daily clinical practice. <h3>Methods</h3> RITAR (RITuximab en Artritis Reumatoide) retrospective, open-label, observational study describes patterns use and tertiary university hospital from 2003 to 2015. We collected demographic, therapeutic...
<h3>Background</h3> Biological therapies (BT) have resulted in a remarkable improvement the treatment of rheumatoid arthritis (RA). One limiting factors for its use is cost. For this reason, development optimization strategies becoming increasingly frequent. <h3>Objectives</h3> To analyze BT RA daily clinical practice. <h3>Methods</h3> We conducted an observational cross-sectional study including all patients with under (except anakinra and rituximab) tertiary referral hospital. Data from...
<h3>Background</h3> For novel direct acting antiviral (DAA) drugs, HIV/hepatitis C virus (HCV) patients have achieved similar sustained virologic response rates as HCV monoinfected patients, but experience in safety and drug interactions with antiretroviral (ARV) regimens are limited clinical practice, especially cirrhotic patients. <h3>Purpose</h3> We evaluated the of DAA ARV drugs co-infected HIV-1, treated at hospital from January to September 2015. <h3>Material methods</h3> HCV/HIV on...
<h3>Background</h3> The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir [TLV], viral NS3 protease inhibitors) has increased recovery rates by up to 70%. However follow-up these patients is necessary due adverse effects (AEs) high cost treatment. <h3>Purpose</h3> To follow pharmacotherapy chronic hepatitis C virus genotype-1. (VHC-1) treated with triple therapy (TT): BOC or TLV, ribavirin peg-interferon. evaluate efficacy treatment describe...
<h3>Background</h3> Sunitinib (SU) is an oral, small-molecule, multi-targeted tyrosine kinase receptor inhibitor that approved for the treatment of renal cell carcinoma (RCC). However, several patients either do not respond to treatment, or they do, but experience significant toxicity. <h3>Purpose</h3> To find genetic markers toxicity and efficacy using a commercially available DNA microarray genotyping system. <h3>Materials Methods</h3> 25 with newly-diagnosed metastatic RCC were evaluated...
<h3>Background</h3> Non-small cell lung cancer (NSCLC) accounts for most cases of cancer. Approximately 40% patients with NSCLC present advanced-stage disease at the time diagnosis. <h3>Purpose</h3> To analyse median overall survival in stage IIIB or IV. <h3>Materials and Methods</h3> Retrospective observational study. Patients IV who started treatment between 01/01/2011 30/06/2011. Data source: Patient medical records, oncology programme (Oncowin) outpatient dispensing record (SAVAC...
<h3>Background</h3> There are two highly selective antibodies to the epidermal growth factor receptor (EGFR): cetuximab (Ig G1 chimeric molecule) and more recently panitumumab (fully humanised IgG2 molecule). Not much information is available about sequential use of these EGFRs. <h3>Purpose</h3> To analyse chemotherapy treatment with EGFR in those patients treated following describe reason for that change. <h3>Materials methods</h3> Retrospective study including during 2009 2010. Information...
<h3>Background and importance</h3> Many patients with moderate–severe COVID-19 develop immune dysregulation characterised by marked activation of innate immunity, elevation acute phase reactants release proinflammatory cytokines (eg, interleukin 1 (IL-1) IL-6), thus creating a hyperinflammatory state. <h3>Aim objectives</h3> To determine the feasibility safety fighting hyperinflammation in refractory using 3 day course low dose subcutaneous anakinra. <h3>Material methods</h3> A prospective...